Tuesday, May 31, 2022

Axcella Therapeutics (AXLA)
Long COVID Enrollment Completed; OHE Trial Suspended

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to restore cellular homeostasis in multiple key biological pathways and improve cellular energetic efficiency. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and non-alcoholic steatohepatitis (NASH), and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Axcella announced that its Phase 2a trial testing AXA-1125 in Long Covid has reached full enrollment. This placebo-controlled trial that enrolled 40 patients with data expected in late 3Q22.  It also announced that the Phase 2 trial for AXA1125 in NASH (non-alcoholic steateohepatitis) is continuing with data announcement expected in early 3Q222, and that the Phase 2 trial in Overt Hepatic Encephalopathy (OHE) has been terminated.

Phase 2a Trial In Long COVID Data Expected In Early 3Q22.  This placebo-controlled trial enrolled 40 patients with  Long COVID symptoms.  Long COVID is estimated to affect about 20% to 30% of the patients who were infected, recovered or were asymptomatic, then develop post-infectious symptoms of fatigue, muscle aches, and clouded thinking (“brain fog”).  AXA1125 has shown improvement in metabolic function that improve energetics and reduce symptoms….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.